# Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

Study · id `cardio:ct-nct03377335` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03377335](<https://clinicaltrials.gov/study/NCT03377335>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03377335

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 186 participants.

## Technical summary

Registry record NCT03377335. Randomized; no masking; primary purpose treatment. Start 2017-12-22 (actual); primary completion 2018-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 186 participants (planned count; ClinicalTrials.gov record NCT03377335, source copy `cardio:ctgov-nct03377335-2018-02-26`, retrieved 2026-10-26)
- Started: 2017-12-22 (actual) (ClinicalTrials.gov record NCT03377335, source copy `cardio:ctgov-nct03377335-2018-02-26`, retrieved 2026-10-26)
- Primary completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT03377335, source copy `cardio:ctgov-nct03377335-2018-02-26`, retrieved 2026-10-26)
- Completion: 2019-01 (anticipated) (ClinicalTrials.gov record NCT03377335, source copy `cardio:ctgov-nct03377335-2018-02-26`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT03377335, source copy `cardio:ctgov-nct03377335-2018-02-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03377335-2018-02-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dapagliflozin 10mg
- Intervention (Drug): Metformin
- Lead sponsor: University of Palermo
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: University of Catania
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Palermo (`cardio:org-university-of-palermo`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 93c9cfa30660ce381960d4aefa59473c178befcb71059669465ea258d6792650
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
